Sort   by:  
 Page size 
UnknownGlycosylation-independent binding of monoclonal antibody toripalimab to FG loop of PD-1 for tumor immune checkpoint therapy.
Not available
S-EPMC6601540 | biostudies-literature
UnknownAxitinib in Combination With Toripalimab, a Humanized Immunoglobulin G4 Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB Trial.
Not available
S-EPMC6839911 | biostudies-literature
UnknownCharacterization of the high-affinity anti-CTLA-4 monoclonal antibody JS007 for immune checkpoint therapy of cancer.
Not available
S-EPMC9754112 | biostudies-literature
UnknownShort-course radiotherapy combined with chemotherapy and PD-1 inhibitor in low-lying early rectal cancer: study protocol for a single-arm, multicentre, prospective, phase II trial (TORCH-E).
Not available
S-EPMC10565143 | biostudies-literature
UnknownPreclinical investigations and a first-in-human phase 1a trial of JS007, a novel anti-CTLA-4 antibody, in patients with advanced solid tumors.
Not available
S-EPMC11443874 | biostudies-literature
UnknownToripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis.
Not available
S-EPMC9066368 | biostudies-literature
UnknownIdentification of a hotspot on PD-L1 for pH-dependent binding by monoclonal antibodies for tumor therapy.
Not available
S-EPMC7445246 | biostudies-literature
UnknownSafety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients.
Not available
S-EPMC6332582 | biostudies-literature
UnknownToripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trial.
Not available
S-EPMC8517012 | biostudies-literature
UnknownTifcemalimab as monotherapy or in combination with toripalimab in patients with relapsed/refractory lymphoma: a Phase I trial.
Not available
S-EPMC12084519 | biostudies-literature
Sort   by:  
 Page size